Tag: Cancer: Bladder
AUA: Outcomes of Robotic, Open Cystectomy Compared in Bladder Cancer
Number of days alive and out of hospital within first 90 days greater for robot-assisted surgery, but clinical significance of findings unclear
AUA: Immunotherapy Aids Survival in Muscle-Invasive Bladder Cancer
Patients receiving nivolumab had an approximately 30 percent lower likelihood of developing cancer recurrence versus placebo
AUA: Pandemic Disruptions Impacted One in Four Prostate, Bladder Cancer Patients
Changes, delays, and cancellation of cancer treatment and ancillary care reported
Recovery From Radical Cystectomy Takes Three to Six Months
No difference seen in percentage of patients recovering at each time point for robot-assisted versus open radical cystectomy
Carbogen and Nicotinamide With Radiation Feasible for Bladder Cancer
Trial involving seven patients with locally advanced bladder cancer shows concurrent CON with radiation therapy feasible in Australia
Adjuvant Nivolumab Slows Muscle-Invasive Urothelial Carcinoma
Disease-free survival was longer with adjuvant nivolumab in intention-to-treat population, for those with PD-L1 expression at least 1 percent
Enfortumab Vedotin Prolongs Survival in Advanced Urothelial Cancer
Overall survival longer compared with standard chemo for disease progression following platinum-based chemo and PD-1 or PD-L1 inhibitor
Aspirin Use Tied to Longer Bladder, Breast Cancer Survival
However, aspirin use in older adults not tied to incidence of various cancer types
Smoking Tied to Worse Bladder Cancer Outcomes After Surgery
